US Family Health Plan

Prior Authorization Request Form for

Liraglutide injection (Saxenda), Semaglutide injection (Wegovy) Tirzepatide injection (Zepbound)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007

Initial therapy approves for 6 months, renewal approves for 12 months. For renewal of therapy an initial USFHP prior authorization approval is required.							
Step	Please complete patient and physician information (please print):						
1	Patient	Name:	Physician Name:				
	Address:		Address:				
	Sponso	or ID #	Phone #:				
	Date of		Secure Fax #:				
Step	tep Please complete the clinical assessment:						
2	1.	Has the patient received this medication under the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for the requested medication.	☐ Yes	□No			
			(subject to verification)	Proceed to question 2			
			Proceed to question 15	·			
	2.	How old is the patient?	☐ Less than 12 years of age - STOP Coverage not approved				
			☐ Greater than or equal to 12 years of age and less than 18 years of age - Proceed to question 3				
			☐ Greater than or equal to 18 years of age - Proceed to question 6				
	3.	Does the patient have BMI GREATER THAN OR EQUAL TO the 95th percentile standardized for age and sex?	☐ Yes	□No			
			Proceed to question 4	STOP			
				Coverage not approved			
	4.	. Has the patient tried and failed or has a contraindication to Qsymia or one of its individual generic components?	☐ Yes	□No			
			Proceed to question 5	STOP			
				Coverage not approved			

US Family Health Plan Prior Authorization Request Form for Liraglutide injection (Saxenda), Semaglutide injection (Wegovy) Tirzepatide injection (Zepbound)

5.	Please provide the date and duration or contraindication for each medication listed below.						
	Note: The dates and durations of therapy for each is listed below must be provided or your case could be		tion to each medication				
	Qsymia or one of its individual generic components	:					
	Date Duration of therapy		n				
	Proceed to	question 9					
6.	Does the patient have BMI GREATER THAN or	☐ Yes	□No				
	EQUAL to 30, or a BMI GREATER THAN or EQUAL to 27 for those with risk factors in	Proceed to question 7	STOP				
	addition to obesity (diabetes, impaired glucose		Coverage not approved				
	tolerance, dyslipidemia, hypertension, sleep apnea)?						
7.	Has the patient tried and failed or has a	☐ Yes	□No				
	contraindication to phentermine, Qsymia or one of its individual generic components, and	Proceed to question 8	STOP				
	Contrave or one of its individual generic		Coverage not approved				
	components?						
8.	Please provide the date and duration or contraindic						
	Note: The dates and durations of therapy for each in listed below must be provided or your case could be		tion to each medication				
Phente	ermine: Date Duration of therapy		dication				
Qsymia	a or one of its individual generic components - topira	mate and phentermine:					
Date _	Duration of therapy	Contraindication _					
Contra	ve or one of its individual generic components - bup	opion and naltrexone:					
Date _	Duration of therapy	Contraindication _					
	Proceed to que	stion 9					
9.	Does the patient have type 2 diabetes?	☐ Yes	□ No				
		Proceed to question 10	Proceed to question 11				
10	. Has the patient tried and failed metformin and the preferred GLP1-RAs (Trulicity)?	☐ Yes	□ No				
	preferred GLF 1-NAS (Trulletty):	Proceed to question 11	STOP				
			Coverage not approved				
	. Will the requested medication be used with	☐ Yes	ПМа				
11.	another GLP1RA (for example, Bydureon,	STOP	□ No				
	Trulicity, Byetta, Adlyxin, Victoza, Soliqua, Xultophy)?	Coverage not approved	Proceed to question 12				
	70110P11J1	Coverage not approved					

US Family Health Plan Prior Authorization Request Form for Liraglutide injection (Saxenda), Semaglutide injection (Wegovy) **Tirzepatide injection (Zepbound)**

	history of medul	have a history of or family lary thyroid cancer, or multiple	□ Yes	□ No
	endocrine neople	endocrine neoplasia syndrome type 2?		Proceed to question 13
			Coverage not approved	
		Has the patient engaged in a trial of behavioral modification and dietary restriction for at least 6 months and has failed to achieve the desired weight loss, and will remain engaged throughout course of therapy?	☐ Yes	□ No
			Proceed to question 14	STOP
				Coverage not approved
	14. Is the patient pre	Is the patient pregnant?	□ Yes	□No
			STOP	Sign and date below
			Coverage not approved	
		Is the patient currently engaged in behavioral modification and on a reduced calorie diet?	□ Yes	□ No
	modification and		Proceed to question 16	STOP
				Coverage not approved
	16. How old is the pa	i. How old is the patient?	☐ Less than 12 years of age - STOP Coverage not approved	
			☐ Greater than or equal to 12 years of age and less than 18 years of age - Proceed to question 18	
			☐ Greater than or equal to 18 years of age - Proceed to question 17	
		Has the patient lost GREATER THAN or EQUAL to 4 percent of baseline body weight since starting medication despite 16 weeks of therapy?	□ Yes	□No
			Proceed to question 19	STOP
				Coverage not approved
		Has the patient experienced a reduction of AT LEAST 5 percent of baseline BMI?	□ Yes	□ No
	LEAST 5 percent		Proceed to question 19	STOP
				Coverage not approved
	19. Is the patient pre	Is the patient pregnant?	☐ Yes	□ No
			STOP	Sign and date below
			Coverage not approved	
Step	I certify the above is tr	ue to the best of my knowledge	e. Please sign and date:	
3				
	Prescriber Signature		Date	